azd3965 has been researched along with Lymphoma* in 1 studies
1 other study(ies) available for azd3965 and Lymphoma
| Article | Year |
|---|---|
MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.
Monocarboxylate transporters (MCT) modulate tumor cell metabolism and offer promising therapeutic targets for cancer treatment. Understanding the impact of MCT blockade on tumor cell metabolism may help develop combination strategies or identify pharmacodynamic biomarkers to support the clinical development of MCT inhibitors now in clinical trials. In this study, we assessed the impact of the MCT1 inhibitor AZD3965 on cancer cell metabolism Topics: Acrylates; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Energy Metabolism; Female; HT29 Cells; Humans; Lactic Acid; Lymphoma; Magnetic Resonance Spectroscopy; Metformin; Mice, SCID; Mitochondria; Monocarboxylic Acid Transporters; Muscle Proteins; Pyrimidinones; Symporters; Thiophenes; Xenograft Model Antitumor Assays | 2017 |